Loading…

Investigating myotoxicity following Australian red-bellied black snake (Pseudechis porphyriacus) envenomation

Background Myotoxicity is one of the common clinical manifestations of red-bellied black snake (Pseudechis porphyriacus) envenomation characterised by elevated creatine kinase (CK) concentrations of greater than 1000 U/L. This study aimed to investigate the occurrence of myotoxicity in patients foll...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2021-09, Vol.16 (9), p.e0256653
Main Authors: Sanhajariya, Suchaya, Duffull, Stephen B, Isbister, Geoffrey K
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c570t-98622ab56a51c44c3273433ede098ddf21fc0932c878f98dd7fcb44f1774e16a3
cites cdi_FETCH-LOGICAL-c570t-98622ab56a51c44c3273433ede098ddf21fc0932c878f98dd7fcb44f1774e16a3
container_end_page
container_issue 9
container_start_page e0256653
container_title PloS one
container_volume 16
creator Sanhajariya, Suchaya
Duffull, Stephen B
Isbister, Geoffrey K
description Background Myotoxicity is one of the common clinical manifestations of red-bellied black snake (Pseudechis porphyriacus) envenomation characterised by elevated creatine kinase (CK) concentrations of greater than 1000 U/L. This study aimed to investigate the occurrence of myotoxicity in patients following envenomation. Methods/Principal findings Patient characteristics and serial blood samples (timed venom concentrations and CK concentrations, pre- and post- antivenom) from 114 patients (median age 41, 2-90y; 80 male) were extracted from the Australian Snakebite Project database. Patients were categorised into three groups based on peak CK concentrations [no myotoxicity (10,000 U/L)]. The odds of (mild or severe) myotoxicity was lower in patients that received early antivenom (within 6 hours post-bite) compared to those that received late or no antivenom (odd ratio was 0.186; 95% confidence interval, 0.052-0.664). A population pharmacokinetic-pharmacodynamic (PKPD) model was developed to describe the relationship between the time course of venom (a mixture of toxins) and effect (elevated CK). In addition, a kinetic-pharmacodynamic (KPD) model was developed to describe the relationship between time course of a theoretical toxin and effect. Model development and parameter estimation was performed using NONMEM v7.3. No single set of parameter values from either the PKPD or KPD models were found that could accurately describe the time course of different levels of severity of myotoxicity. The predicted theoretical toxin half-life from the KPD model was 11 ± 3.9 hours compared to the half-life of venom of 5.3 ± 0.36 hours. This indicates that the putative causative toxin's concentration-time profile does not parallel that of venom. Conclusion Early antivenom administration reduces the incidence of myotoxicity. The venom concentration profile does not appear to be the driver for myotoxicity following envenomation. Additional factors that affect the sensitivity of the patient to snake venom/toxins must be explored to understand the relationship with myotoxicity.
doi_str_mv 10.1371/journal.pone.0256653
format article
fullrecord <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2571447014</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A674968892</galeid><doaj_id>oai_doaj_org_article_07d8bb3a936b41eaa3a7891a02b09df4</doaj_id><sourcerecordid>A674968892</sourcerecordid><originalsourceid>FETCH-LOGICAL-c570t-98622ab56a51c44c3273433ede098ddf21fc0932c878f98dd7fcb44f1774e16a3</originalsourceid><addsrcrecordid>eNp1UsuO0zAUjRCIGQb-AIlIbGDR4ldsZ4NUjXhUGgkWsLZu_Gg9k9jFTgb69zg0ICqBvLB1fO65x9enqp5jtMZU4De3cUoB-vUhBrtGpOG8oQ-qS9xSsuIE0Yd_nS-qJznfItRQyfnj6oKyBhU6vqyGbbi3efQ7GH3Y1cMxjvGH13481i72ffw-o5spjwl6D6FO1qw62_femrrrQd_VOcCdrV99znYyVu99rg8xHfbH5EFP-XVtS4MQh6Ifw9PqkYM-22fLflV9ff_uy_XH1c2nD9vrzc1KNwKNq1ZyQqBrODRYM6YpEZRRao1FrTTGEew0Km_TUkg3I8LpjjGHhWAWc6BX1YuT7qGPWS2Tyoo0AjMmEGaFsT0xTIRbdUh-gHRUEbz6BcS0U5BGr3urkDCy6yi0lHcMWwAKQrYYEOlQa9ys9XbpNnWDNdqGeVpnouc3we_VLt4rySiRYhZ4uQik-G0q3_EfywtrB8WVDy4WMT34rNWGC9ZyKVtSWOt_sMoydvC6ZMX5gp8VsFOBTjHnZN0f4xipOWm_zag5aWpJGv0JQ4PJbA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2571447014</pqid></control><display><type>article</type><title>Investigating myotoxicity following Australian red-bellied black snake (Pseudechis porphyriacus) envenomation</title><source>Publicly Available Content (ProQuest)</source><source>PubMed Central</source><creator>Sanhajariya, Suchaya ; Duffull, Stephen B ; Isbister, Geoffrey K</creator><contributor>Gutiérrez, José María</contributor><creatorcontrib>Sanhajariya, Suchaya ; Duffull, Stephen B ; Isbister, Geoffrey K ; Gutiérrez, José María</creatorcontrib><description>Background Myotoxicity is one of the common clinical manifestations of red-bellied black snake (Pseudechis porphyriacus) envenomation characterised by elevated creatine kinase (CK) concentrations of greater than 1000 U/L. This study aimed to investigate the occurrence of myotoxicity in patients following envenomation. Methods/Principal findings Patient characteristics and serial blood samples (timed venom concentrations and CK concentrations, pre- and post- antivenom) from 114 patients (median age 41, 2-90y; 80 male) were extracted from the Australian Snakebite Project database. Patients were categorised into three groups based on peak CK concentrations [no myotoxicity (10,000 U/L)]. The odds of (mild or severe) myotoxicity was lower in patients that received early antivenom (within 6 hours post-bite) compared to those that received late or no antivenom (odd ratio was 0.186; 95% confidence interval, 0.052-0.664). A population pharmacokinetic-pharmacodynamic (PKPD) model was developed to describe the relationship between the time course of venom (a mixture of toxins) and effect (elevated CK). In addition, a kinetic-pharmacodynamic (KPD) model was developed to describe the relationship between time course of a theoretical toxin and effect. Model development and parameter estimation was performed using NONMEM v7.3. No single set of parameter values from either the PKPD or KPD models were found that could accurately describe the time course of different levels of severity of myotoxicity. The predicted theoretical toxin half-life from the KPD model was 11 ± 3.9 hours compared to the half-life of venom of 5.3 ± 0.36 hours. This indicates that the putative causative toxin's concentration-time profile does not parallel that of venom. Conclusion Early antivenom administration reduces the incidence of myotoxicity. The venom concentration profile does not appear to be the driver for myotoxicity following envenomation. Additional factors that affect the sensitivity of the patient to snake venom/toxins must be explored to understand the relationship with myotoxicity.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0256653</identifier><identifier>PMID: 34506531</identifier><language>eng</language><publisher>San Francisco: Public Library of Science</publisher><subject>Antivenom ; Biology and Life Sciences ; Bites and stings ; Confidence intervals ; Creatine ; Creatine kinase ; Ethics ; Half-life ; Health services ; Kinases ; Mathematical models ; Medicine and Health Sciences ; Parameter estimation ; Patients ; Pharmacodynamics ; Pharmacokinetics ; Pharmacology ; Pharmacy ; Physical Sciences ; Prevention ; Pseudechis porphyriacus ; Snake bites ; Snakes ; Toxicology ; Toxins ; Venom</subject><ispartof>PloS one, 2021-09, Vol.16 (9), p.e0256653</ispartof><rights>COPYRIGHT 2021 Public Library of Science</rights><rights>2021 Sanhajariya et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 Sanhajariya et al 2021 Sanhajariya et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c570t-98622ab56a51c44c3273433ede098ddf21fc0932c878f98dd7fcb44f1774e16a3</citedby><cites>FETCH-LOGICAL-c570t-98622ab56a51c44c3273433ede098ddf21fc0932c878f98dd7fcb44f1774e16a3</cites><orcidid>0000-0002-7987-6296</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2571447014/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2571447014?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,44590,53791,53793,74998</link.rule.ids></links><search><contributor>Gutiérrez, José María</contributor><creatorcontrib>Sanhajariya, Suchaya</creatorcontrib><creatorcontrib>Duffull, Stephen B</creatorcontrib><creatorcontrib>Isbister, Geoffrey K</creatorcontrib><title>Investigating myotoxicity following Australian red-bellied black snake (Pseudechis porphyriacus) envenomation</title><title>PloS one</title><description>Background Myotoxicity is one of the common clinical manifestations of red-bellied black snake (Pseudechis porphyriacus) envenomation characterised by elevated creatine kinase (CK) concentrations of greater than 1000 U/L. This study aimed to investigate the occurrence of myotoxicity in patients following envenomation. Methods/Principal findings Patient characteristics and serial blood samples (timed venom concentrations and CK concentrations, pre- and post- antivenom) from 114 patients (median age 41, 2-90y; 80 male) were extracted from the Australian Snakebite Project database. Patients were categorised into three groups based on peak CK concentrations [no myotoxicity (10,000 U/L)]. The odds of (mild or severe) myotoxicity was lower in patients that received early antivenom (within 6 hours post-bite) compared to those that received late or no antivenom (odd ratio was 0.186; 95% confidence interval, 0.052-0.664). A population pharmacokinetic-pharmacodynamic (PKPD) model was developed to describe the relationship between the time course of venom (a mixture of toxins) and effect (elevated CK). In addition, a kinetic-pharmacodynamic (KPD) model was developed to describe the relationship between time course of a theoretical toxin and effect. Model development and parameter estimation was performed using NONMEM v7.3. No single set of parameter values from either the PKPD or KPD models were found that could accurately describe the time course of different levels of severity of myotoxicity. The predicted theoretical toxin half-life from the KPD model was 11 ± 3.9 hours compared to the half-life of venom of 5.3 ± 0.36 hours. This indicates that the putative causative toxin's concentration-time profile does not parallel that of venom. Conclusion Early antivenom administration reduces the incidence of myotoxicity. The venom concentration profile does not appear to be the driver for myotoxicity following envenomation. Additional factors that affect the sensitivity of the patient to snake venom/toxins must be explored to understand the relationship with myotoxicity.</description><subject>Antivenom</subject><subject>Biology and Life Sciences</subject><subject>Bites and stings</subject><subject>Confidence intervals</subject><subject>Creatine</subject><subject>Creatine kinase</subject><subject>Ethics</subject><subject>Half-life</subject><subject>Health services</subject><subject>Kinases</subject><subject>Mathematical models</subject><subject>Medicine and Health Sciences</subject><subject>Parameter estimation</subject><subject>Patients</subject><subject>Pharmacodynamics</subject><subject>Pharmacokinetics</subject><subject>Pharmacology</subject><subject>Pharmacy</subject><subject>Physical Sciences</subject><subject>Prevention</subject><subject>Pseudechis porphyriacus</subject><subject>Snake bites</subject><subject>Snakes</subject><subject>Toxicology</subject><subject>Toxins</subject><subject>Venom</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp1UsuO0zAUjRCIGQb-AIlIbGDR4ldsZ4NUjXhUGgkWsLZu_Gg9k9jFTgb69zg0ICqBvLB1fO65x9enqp5jtMZU4De3cUoB-vUhBrtGpOG8oQ-qS9xSsuIE0Yd_nS-qJznfItRQyfnj6oKyBhU6vqyGbbi3efQ7GH3Y1cMxjvGH13481i72ffw-o5spjwl6D6FO1qw62_femrrrQd_VOcCdrV99znYyVu99rg8xHfbH5EFP-XVtS4MQh6Ifw9PqkYM-22fLflV9ff_uy_XH1c2nD9vrzc1KNwKNq1ZyQqBrODRYM6YpEZRRao1FrTTGEew0Km_TUkg3I8LpjjGHhWAWc6BX1YuT7qGPWS2Tyoo0AjMmEGaFsT0xTIRbdUh-gHRUEbz6BcS0U5BGr3urkDCy6yi0lHcMWwAKQrYYEOlQa9ys9XbpNnWDNdqGeVpnouc3we_VLt4rySiRYhZ4uQik-G0q3_EfywtrB8WVDy4WMT34rNWGC9ZyKVtSWOt_sMoydvC6ZMX5gp8VsFOBTjHnZN0f4xipOWm_zag5aWpJGv0JQ4PJbA</recordid><startdate>20210910</startdate><enddate>20210910</enddate><creator>Sanhajariya, Suchaya</creator><creator>Duffull, Stephen B</creator><creator>Isbister, Geoffrey K</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-7987-6296</orcidid></search><sort><creationdate>20210910</creationdate><title>Investigating myotoxicity following Australian red-bellied black snake (Pseudechis porphyriacus) envenomation</title><author>Sanhajariya, Suchaya ; Duffull, Stephen B ; Isbister, Geoffrey K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c570t-98622ab56a51c44c3273433ede098ddf21fc0932c878f98dd7fcb44f1774e16a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antivenom</topic><topic>Biology and Life Sciences</topic><topic>Bites and stings</topic><topic>Confidence intervals</topic><topic>Creatine</topic><topic>Creatine kinase</topic><topic>Ethics</topic><topic>Half-life</topic><topic>Health services</topic><topic>Kinases</topic><topic>Mathematical models</topic><topic>Medicine and Health Sciences</topic><topic>Parameter estimation</topic><topic>Patients</topic><topic>Pharmacodynamics</topic><topic>Pharmacokinetics</topic><topic>Pharmacology</topic><topic>Pharmacy</topic><topic>Physical Sciences</topic><topic>Prevention</topic><topic>Pseudechis porphyriacus</topic><topic>Snake bites</topic><topic>Snakes</topic><topic>Toxicology</topic><topic>Toxins</topic><topic>Venom</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sanhajariya, Suchaya</creatorcontrib><creatorcontrib>Duffull, Stephen B</creatorcontrib><creatorcontrib>Isbister, Geoffrey K</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Proquest Nursing &amp; Allied Health Source</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological &amp; Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>ProQuest_Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science &amp; Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>Advanced Technologies &amp; Aerospace Database‎ (1962 - current)</collection><collection>Agricultural &amp; Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>https://resources.nclive.org/materials</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Meteorological &amp; Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agriculture Science Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Advanced Technologies &amp; Aerospace Database</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sanhajariya, Suchaya</au><au>Duffull, Stephen B</au><au>Isbister, Geoffrey K</au><au>Gutiérrez, José María</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Investigating myotoxicity following Australian red-bellied black snake (Pseudechis porphyriacus) envenomation</atitle><jtitle>PloS one</jtitle><date>2021-09-10</date><risdate>2021</risdate><volume>16</volume><issue>9</issue><spage>e0256653</spage><pages>e0256653-</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Background Myotoxicity is one of the common clinical manifestations of red-bellied black snake (Pseudechis porphyriacus) envenomation characterised by elevated creatine kinase (CK) concentrations of greater than 1000 U/L. This study aimed to investigate the occurrence of myotoxicity in patients following envenomation. Methods/Principal findings Patient characteristics and serial blood samples (timed venom concentrations and CK concentrations, pre- and post- antivenom) from 114 patients (median age 41, 2-90y; 80 male) were extracted from the Australian Snakebite Project database. Patients were categorised into three groups based on peak CK concentrations [no myotoxicity (10,000 U/L)]. The odds of (mild or severe) myotoxicity was lower in patients that received early antivenom (within 6 hours post-bite) compared to those that received late or no antivenom (odd ratio was 0.186; 95% confidence interval, 0.052-0.664). A population pharmacokinetic-pharmacodynamic (PKPD) model was developed to describe the relationship between the time course of venom (a mixture of toxins) and effect (elevated CK). In addition, a kinetic-pharmacodynamic (KPD) model was developed to describe the relationship between time course of a theoretical toxin and effect. Model development and parameter estimation was performed using NONMEM v7.3. No single set of parameter values from either the PKPD or KPD models were found that could accurately describe the time course of different levels of severity of myotoxicity. The predicted theoretical toxin half-life from the KPD model was 11 ± 3.9 hours compared to the half-life of venom of 5.3 ± 0.36 hours. This indicates that the putative causative toxin's concentration-time profile does not parallel that of venom. Conclusion Early antivenom administration reduces the incidence of myotoxicity. The venom concentration profile does not appear to be the driver for myotoxicity following envenomation. Additional factors that affect the sensitivity of the patient to snake venom/toxins must be explored to understand the relationship with myotoxicity.</abstract><cop>San Francisco</cop><pub>Public Library of Science</pub><pmid>34506531</pmid><doi>10.1371/journal.pone.0256653</doi><orcidid>https://orcid.org/0000-0002-7987-6296</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1932-6203
ispartof PloS one, 2021-09, Vol.16 (9), p.e0256653
issn 1932-6203
1932-6203
language eng
recordid cdi_plos_journals_2571447014
source Publicly Available Content (ProQuest); PubMed Central
subjects Antivenom
Biology and Life Sciences
Bites and stings
Confidence intervals
Creatine
Creatine kinase
Ethics
Half-life
Health services
Kinases
Mathematical models
Medicine and Health Sciences
Parameter estimation
Patients
Pharmacodynamics
Pharmacokinetics
Pharmacology
Pharmacy
Physical Sciences
Prevention
Pseudechis porphyriacus
Snake bites
Snakes
Toxicology
Toxins
Venom
title Investigating myotoxicity following Australian red-bellied black snake (Pseudechis porphyriacus) envenomation
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T14%3A41%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Investigating%20myotoxicity%20following%20Australian%20red-bellied%20black%20snake%20(Pseudechis%20porphyriacus)%20envenomation&rft.jtitle=PloS%20one&rft.au=Sanhajariya,%20Suchaya&rft.date=2021-09-10&rft.volume=16&rft.issue=9&rft.spage=e0256653&rft.pages=e0256653-&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0256653&rft_dat=%3Cgale_plos_%3EA674968892%3C/gale_plos_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c570t-98622ab56a51c44c3273433ede098ddf21fc0932c878f98dd7fcb44f1774e16a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2571447014&rft_id=info:pmid/34506531&rft_galeid=A674968892&rfr_iscdi=true